ALCJ.PA Crossject Société Anonyme Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:57
Feb 07
Feb 07
Crossject long: BARDA contract, FDA EUA catalyst, cheap vs deal
The author argues Crossject's ZENEO needle-free emergency auto-injector is validated by a signed BARDA framework worth up to $155M (roughly $60M firm initial stockpile order, ~$32M development funding, up to $63M in options) while the market cap sits near $100M, so investors are paying less than the committed US government contract value. The mechanism is that FDA Emergency Use Authorization for ZENEO ZEPIZURE (midazolam) would immediately trigger the initial BARDA stockpile order, de-risk the platform for defense and big-pharma partners, and open a multi-billion market across epilepsy, anaphylaxis and naloxone with a 400+ patent wall limiting competition. The author states main risks as historical delays and dilution common to small medtechs, while describing the timeframe loosely as 'over time' with a 2-5x scenario if the EUA is granted and execution is decent.
HIGH
About ALCJ.PA Investor Commentary
Across the available history and selected sources, Buzzberg tracks ALCJ.PA (Crossject Société Anonyme) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/ZZerozen.